While impressive progress has been made in the clinical application of immunomodulatory agents, there are still some problems, such as CD33 and CD123 also expressed in normal hematopoietic cells, some AML patients not sensitive to anti-PD-1/PD-L1 [17]. This evidence concerns the gene CD33 and acute myeloid leukemia.